SN132D not checked

Spago Nanomedical AB

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Endometriosis, Breast Cancer, Pancreas Cancer
Main trialPhase 2
“This is a Phase IIa, open-label, non-randomised and non-placebo-controlled study. The study is designed to evaluate the diagnostic value and safety of a single intravenous dose of SN132D in up to 18 participants with suspected endometriosis. Magnetic resonance imaging (MRI) will be performed pre- and post-infusion of SN132D.”In the company’s words, NCT05664828 on ClinicalTrials.gov
Other names
SpagoPix

Other drugs for Endometriosis

All 8 drugs for Endometriosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Completed 20 Jun 2023 Efficacy of SN132D in Patients With Suspected Endometriosis
Phase 1Completed 30 Nov 2022 A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SN132D

Following is part of Solo: you see every change to SN132D the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in